Drug discovery: Lead compound identification
Drug Optimisation
Drug Development: pre-clinical research, clinical trials, and regulatory approval to market the drug.
Pharmacokinetics: medicinal chemistry point of view.
Cardiovascular drugs:
− Drugs affecting Renin-Angiotensin System:
∙ ACE inhibitors
∙ Angiotensin II Receptor Antagonists
∙ Renin Inhibitors
− Diuretics:
∙ Thiazide Diuretics
∙ Loop Diuretics
∙ Potassium-sparing Diuretics
∙ Osmotic diuretics
− Cardiotonics and Antilipidemic Agents
∙ Cardiac Glycosides
∙ Inotropes
∙ Resins and Niacin
∙ Fibrates
∙ Statins
− Vasodilators:
∙ Calcium Channel Blockers/Calcium Antagonists
∙ Antianginals (Organonitrates)
∙ Miscellaneous Agents
Coagulation modifiers:
− Anticoagulants:
∙ Coumarins and Indandiones
∙ Factor Xa Inhibitors
∙ Heparins
∙ Thrombin Inhibitors
− Antiplatelet Agents
∙ Glycoprotein Platelet Inhibitors
∙ Platelet Aggregation Inhibitors
− Heparin Antagonists
− Miscellaneous Coagulation Modifiers
− Platelet-Stimulating Agents
− Thrombolytics
Drugs acting on Serotonin (5-hydroxytryptamine) receptors:
− Antimigrane agents
− Ergot Alkaloids
− Prokinetics
− Anti-hemesys
Agents for the Treatment of Peptic Ulcers:
- Proton Pump Inhibitors